Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Near-infrared fluorescence molecular endoscopy with topical Bevacizumab-800CW for early neoplasia detection in Barrett's esophagus
NL-OMON55871Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Nov 2018
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab-IRDye800CW, indocyanine green, cetuximab-IRDye 800CW in Barrett's esophagus, esophageal adenocarcinoma (EAC), sponsored by University Medical Center Groningen. Started Nov 2018; status: active, not recruiting.
02
Drugs
bevacizumab-IRDye800CWindocyanine greencetuximab-IRDye 800CW
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NL-OMON55871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55871.